• Fengrong Zuo, Senior Scientist, MedImmune
• Matthew Peters, Principal Scientist, AstraZeneca
• Nathan Bays, Research Fellow in Cellular Pharmacology, Merck Research Labs
• Regis Doyonnas, Senior Principle Scientist, Pfizer
• Tetsuro Wakatsuki, Co-Founder & Chief Scientific Officer, InvivoSciences
• Peter Sartipy, Senior Principal Scientist, Department Head, Cellectis Stem Cells
• Grant Cameron , RAFT Development Director, TAP Biosystems
• Grace Wong, CEO, Actokine Therapeutics
• Thorsten Gorba, Director CNS Assay Screening and Development, StemCells, Inc
• Jessica Carmen, Scientist, Lonza
• Mark Slack, Group Leader, Evotec
• Deborah Moshinsky, Founder and President, Cell Assay Innovations
• Mehmet Fatih Yanik, Associate Professor, MIT
• Marcie Glicksman, Director of Leads discovery, Harvard University
• Anne Carpenter, Director of Director, Imaging Platform, Broad Institute of Harvard and MIT
Drugs recalls due to toxicity not only have a huge effect on the cost of developing new therapeutics but it also leads to many years of wasted research. That is why it is vital to get things right from the outset with more precise testing of new leads using more accurate in-vitro models. High Throughput Screening using biochemical assays has been a mainstay of the pharmaceutical industry in the past, but with the cost of developing a single lead reaching exorbitant amounts, it is now necessary to look at more cost-efficient methods that more accurately represent the in-vivo environment.
The cell based assay platform has now been integrated into the HTS pipeline to provide more accurate analyses of new drug leads and their activity in-vivo. It already makes up 50% of the HTS activity by the top pharmaceutical companies and the industry is set to grow at a rate of 15% CAGR by 20151. Advances in stem cell technologies provide a way to obtain plentiful human cell lines instead of using cancerous and animal cells for assays. In addition to being a more accurate platform for developing drugs, it also reduces costs incurred by toxicology testing in animals and mitigates the risk of future recalls.
Visiongain’s 3rd Annual Cell Based Assays conference will be taking place in Boston for the first time. This event will provide a unique networking event to boost your understanding of:
• Future growth opportunities in the cell based assays market
• How to reduce costs in the drug development process and produce more accurate results earlier.
• Explore new techniques for lead discovery and target identification
• Discover advances in core components required for the cell based assay platform
• Novel outputs using label-free detection methods that reduce interference in cellular signaling
• Developments in software analysis for the outputs generated by different cell based assays
• Cell culture advances and methodology as the platform moves from 2D to 3D
• Cell procurement using induced pluripotent stem cells to mimic human disease pathology!
• Recreating more accurate models of human disease and their response to new drugs
• Advances in process automation and management of data.
Who should attend?
Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders in:
• Bioanalytical Development
• High-Throughput/High-Content Screening Operations
• Compound Profiling
• Drug Discovery/Validation
• Drug Delivery
• Lead Generation
• In Vitro Sciences
• Pre-clinical Development
• Medicinal Chemistry
• Stem Cell Technologies & Platforms
• Pharmacovigilance and Safety Testing
• Chemistry and Bioapplications
• GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Global Research and Development
• Business Development
• Investment and Venture Capital